Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05763407 · ClinicalTrials.gov registry record · NA

Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)

A NA study of Heart Failure, sponsored by Foundry Innovation & Research 1, Limited (FIRE1).

Recruiting
Registry status
NA
Development phase
25
Enrollment target
8
Study locations

NCT05763407 is a NA study of Heart Failure that is actively recruiting participants, run by Foundry Innovation & Research 1, Limited (FIRE1). The registered enrollment target is 25 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05763407, a NA study of Heart Failure, is actively recruiting participants, sponsored by Foundry Innovation & Research 1, Limited (FIRE1).

RECRUITING
Registry status
NA
Development phase
25 participants
Enrollment target
8
Study locations

Study Summary

Early Feasibility Study of the NORM™ System in Heart Failure Patients

Conditions Studied

Interventions

  • DEVICE NORM™ System

Study Locations (8)

New York

  • Columbia University Irving Medical Center/ New York Presbyterian Hospital - New York
  • Rochester General Hospital - Rochester

Ohio

  • Cleveland Clinic - Cleveland
  • The Ohio State University Wexner Medical Center - Columbus

Minnesota

  • University of Minnesota Medica Center - Minneapolis

North Carolina

  • Duke University Medical Center - Durham

South Carolina

  • Prisma Health - Greenville

Texas

  • Austin Heart Central at the Heart Hospital of Austin - Austin

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-06-19
Est. Completion 2027-12
Phase NA

What the Registry Record Tells You About NCT05763407

The ClinicalTrials.gov registry entry for NCT05763407 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Foundry Innovation & Research 1, Limited (FIRE1), which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which NORM™ System is the first listed.

NCT05763407 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Ohio, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05763407 about?

NCT05763407 is a clinical study titled "Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)". Early Feasibility Study of the NORM™ System in Heart Failure Patients

What is the current status of trial NCT05763407?

This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2023-06-19. Estimated completion is 2027-12.

What conditions does trial NCT05763407 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT05763407?

The interventions under investigation include: NORM™ System (DEVICE).

Who is sponsoring clinical trial NCT05763407?

This trial is sponsored by Foundry Innovation & Research 1, Limited (FIRE1), which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05763407 being conducted?

This trial has 8 study locations across Minnesota, New York, North Carolina, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.